These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 18784279)

  • 21. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
    Desjardins A; Reardon DA; Herndon JE; Marcello J; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Bailey L; Bigner DD; Friedman AH; Friedman HS; Vredenburgh JJ
    Clin Cancer Res; 2008 Nov; 14(21):7068-73. PubMed ID: 18981004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.
    Crews KR; Stewart CF; Jones-Wallace D; Thompson SJ; Houghton PJ; Heideman RL; Fouladi M; Bowers DC; Chintagumpala MM; Gajjar A
    Clin Cancer Res; 2002 Jul; 8(7):2202-9. PubMed ID: 12114421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
    Castellino RC; Elion GB; Keir ST; Houghton PJ; Johnson SP; Bigner DD; Friedman HS
    Cancer Chemother Pharmacol; 2000; 45(4):345-9. PubMed ID: 10755324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results.
    Santisteban M; Buckner JC; Reid JM; Wu W; Scheithauer BW; Ames MM; Felten SJ; Nikcevich DA; Wiesenfeld M; Jaeckle KA; Galanis E;
    J Neurooncol; 2009 Apr; 92(2):165-75. PubMed ID: 19066728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alternative chemotherapeutic agents: nitrosoureas, cisplatin, irinotecan.
    Carrillo JA; Munoz CA
    Neurosurg Clin N Am; 2012 Apr; 23(2):297-306, ix. PubMed ID: 22440873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis.
    Xu T; Chen J; Lu Y; Wolff JE
    BMC Cancer; 2010 Jun; 10():252. PubMed ID: 20525214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma.
    Parker RJ; Fruehauf JP; Mehta R; Filka E; Cloughesy T
    J Neurooncol; 2004 Feb; 66(3):365-75. PubMed ID: 15015670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CPT-11 (irinotecan) in the treatment of colorectal cancer.
    Armand JP; Ducreux M; Mahjoubi M; Abigerges D; Bugat R; Chabot G; Herait P; de Forni M; Rougier P
    Eur J Cancer; 1995; 31A(7-8):1283-7. PubMed ID: 7577037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.
    Kang TY; Jin T; Elinzano H; Peereboom D
    J Neurooncol; 2008 Aug; 89(1):113-8. PubMed ID: 18438609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Irinotecan for the treatment of cervical cancer.
    Verschraegen CF
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):32-4. PubMed ID: 12109804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
    Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Friedman HS
    Cancer; 2009 Jul; 115(13):2964-70. PubMed ID: 19402172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of the clinical experience with irinotecan (CPT-11).
    Horowitz RW; Wadler S; Wiernik PH
    Am J Ther; 1997; 4(5-6):203-10. PubMed ID: 10423612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
    Goldwirt L; Beccaria K; Carpentier A; Idbaih A; Schmitt C; Levasseur C; Labussiere M; Milane A; Farinotti R; Fernandez C
    J Neurooncol; 2015 Apr; 122(2):273-81. PubMed ID: 25794638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas.
    de Groot JF; Yung WK
    Cancer J; 2008; 14(5):279-85. PubMed ID: 18836331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Irinotecan therapy in adults with recurrent or progressive malignant glioma.
    Friedman HS; Petros WP; Friedman AH; Schaaf LJ; Kerby T; Lawyer J; Parry M; Houghton PJ; Lovell S; Rasheed K; Cloughsey T; Stewart ES; Colvin OM; Provenzale JM; McLendon RE; Bigner DD; Cokgor I; Haglund M; Rich J; Ashley D; Malczyn J; Elfring GL; Miller LL
    J Clin Oncol; 1999 May; 17(5):1516-25. PubMed ID: 10334539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
    Coggins CA; Elion GB; Houghton PJ; Hare CB; Keir S; Colvin OM; Bigner DD; Friedman HS
    Cancer Chemother Pharmacol; 1998; 41(6):485-90. PubMed ID: 9554593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New chemotherapy options for the treatment of malignant gliomas.
    Burton E; Prados M
    Curr Opin Oncol; 1999 May; 11(3):157-61. PubMed ID: 10328588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas?
    Omuro AM; Delattre JY
    Curr Opin Neurol; 2008 Dec; 21(6):717-9. PubMed ID: 18989118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of irinotecan in pediatric patients with malignant solid tumors.
    Mugishima H; Matsunaga T; Yagi K; Asami K; Mimaya J; Suita S; Kishimoto T; Sawada T; Tsuchida Y; Kaneko M
    J Pediatr Hematol Oncol; 2002 Feb; 24(2):94-100. PubMed ID: 11990713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-angiogenic therapy for high-grade glioma.
    Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.